Serum ferritin, hemoglobin, and Helicobacter pylori infection: A seroepidemiologic survey comprising 2794 Danish adults

Milman, Nils; Rosenstock, Steffen Jais; Andersen, Leif Percival; Jørgensen, Torben; Bonnevie, O

doi:10.1016/s0016-5085(98)70192-1

Cited by 168 publications

(200 citation statements)

References 35 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…25 Recent large sample surveys in Western countries have shown that the prevalence of H. pylori infection is 15-43%, [26][27][28][29] but our study results confirm a higher prevalence in Japan.…”

Section: Discussioncontrasting

confidence: 46%

Prevalence of Helicobacter Pylori Infection and Its Link to Coronary Risk Factors in Japanese Patients With Acute Myocardial Infarction

Kinjo

Sato

et al. 2002

Circ J

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 46%

Prevalence of Helicobacter Pylori Infection and Its Link to Coronary Risk Factors in Japanese Patients With Acute Myocardial Infarction

Kinjo

Sato

et al. 2002

Circ J

View full text Add to dashboard Cite

“…A double-blind, placebo-controlled trial performed in adolescents with IDA and H pylori infection suggested that SF was significantly lower in the H pylori-infected group and that H pylori eradication led to resolution of iron deficiency [15,16] . A large serosurvey of H pylori in adults also found that SF was significantly lower in adults positive for H pylori IgG than that in non-infected controls [17,18] . Based on our medical records of adult patients with chronic gastritis, we found that IDA occurred more frequently in H pylori-positive cases.…”

Section: Discussionmentioning

confidence: 99%

Effects ofH pyloritherapy on erythrocytic and iron parameters in iron deficiency anemia patients withH pylori-positive chronic gastristis

Chen

Luo²

2007

WJG

View full text Add to dashboard Cite

AIM: To elucidate the influences of H pylori infection on oral iron treatment for iron deficiency anemia (IDA). METHODS:A total of 86 patients were divided into two groups: group A, receiving ferrous succinate combined with triple therapy for H pylori eradication, and group B (control), treated with ferrous succinate only. During treatment of IDA, dynamic changes in hemoglobin (Hb) level, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), serum iron (SI), and serum ferritin (SF) were compared between the groups. RESULTS:Hb was slightly higher in group A at d 14 after the start of triple therapy for H pylori eradication (P > 0.05). After the therapy, the increase of Hb in group A became significantly faster than that in group B (P < 0.05). At d 56, the mean Hb in group A returned to the normal level, however, in group B, it was lower than that in group A (P < 0.05) although it had also increased compared with that before oral iron treatment. The MCV and MCH in group A recovered to the normal level, and were much higher than those in group B (P < 0.05) at d 21. In Group B, the MCV and MCH remained at lower than normal levels until d 42 after the start of therapy. And then, they reached a plateau in both groups and the differences disappeared (P > 0.05). The SF in group A was higher than that in group B (P < 0.05) 28 d after the treatment and its improvement was quicker in group A (P < 0.05) , and the difference between the two groups was even more significant (P < 0.01) at d 56. The SI in group A was higher than that in group B (P < 0.05) at d 14 and this persisted until d 56 when the follow-up of this research was finished. CONCLUSION:

show abstract

“…This positive rate was comparable to that in many previous reports. [16][17][18][19][20] Despite the administration of antibiotics at high doses, H. pylori antibodies remained positive throughout the course after BMT in many (70%) of these patients. The results obtained in the present study appear to support the fact that many patients in whom H. pylori infection has resolved have residual antibody titers in the serum as described in Materials and methods.…”

Section: Discussionmentioning

confidence: 99%

Influence of Helicobacter pylori on platelets after bone marrow transplantation from unrelated donors

Wakae

Takatsuka

Mori

et al. 2003

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:This study was performed to clarify the influence of Helicobacter pylori on the platelet count in patients undergoing bone marrow transplantation (BMT) from unrelated donors. Of 23 consecutive patients undergoing BMT from unrelated donors, the H. pylori antibody test did not change from before conditioning until recovery of the platelet count in 15 patients. These patients were classified into H. pylori antibody-positive (n ¼ 8) and -negative (n ¼ 7) groups. In the H. pylori antibody-positive group, the platelet count exceeded 20 Â 10 9 /l significantly faster after BMT, than in the H. pylori antibody-negative group. When myelosuppression was most severe, the interleukin-6 (IL-6) level was significantly higher in the positive group than in the negative group (67.0710.6 vs 9.972.4 pg/ml, Po0.05). In addition, the thrombopoietin level was significantly lower in the positive group than in the negative (510.17313.9 vs 3209.172006.7 pg/ml, Po0.01). These data suggest that H. pylori infection accelerates recovery of the platelet count after BMT from unrelated donors, possibly by stimulating IL-6 production.

show abstract

Serum ferritin, hemoglobin, and Helicobacter pylori infection: A seroepidemiologic survey comprising 2794 Danish adults

Cited by 168 publications

References 35 publications

Prevalence of Helicobacter Pylori Infection and Its Link to Coronary Risk Factors in Japanese Patients With Acute Myocardial Infarction

Prevalence of Helicobacter Pylori Infection and Its Link to Coronary Risk Factors in Japanese Patients With Acute Myocardial Infarction

Effects ofH pyloritherapy on erythrocytic and iron parameters in iron deficiency anemia patients withH pylori-positive chronic gastristis

Influence of Helicobacter pylori on platelets after bone marrow transplantation from unrelated donors

Contact Info

Product

Resources

About